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Prognosis of conjunctival melanomas in relation to histopathological
features
U. Fuchs*, T. Kivela, K. Liesto & A. Tarkkanen
Department of Ophthalmology, Helsinki University Central Hospital, Haartmaninkatu 4 C, SF-00290 Helsinki, Finland.
Summary Twenty-six patients (age 29-85 years) with primary malignant melanoma of the conjunctiva were
analysed for usefulness of various histopathological and immunohistochemical features of the primary,
recurrent and metastatic tumours in evaluating their prognosis. The mean follow-up time was 5.5 years,
ranging from 8 months to 17 years. Eight patients developed metastases and seven have died. The mean time
from diagnosis to death due to metastasis was 3.8 years (range 1-6 years). The site of the primary tumour
seemed to be most closely correlated to high metastatic risk. Only two of the sixteen limbal melanomas
metastasised, whereas two of the four bulbar, all three tarsal and the only diffuse primary tumour caused
metastatic disease. Two of the metastasising primary tumours were less than 1.5mm thick, but all exceeded
0.8mm in thickness. The mitotic rate, the amount of inflammatory infiltrate, the cell type or the presence of
adjacent intraepithelial involvement did not obviously correlate to treatment outcome. Furthermore, the
expression of S-100 protein and neuron-specific enolase (NSE), both suggested to be prognostic indicators in
cutaneous melanoma, did not correlate to the tendency of the conjunctival melanomas to recur or metastasise.
Primary malignant melanoma of the conjunctiva is a rare
neoplasm comprising less than 1% of malignant tumours of
the eye (Grossniklaus et al., 1987). In spite of many recent
studies on the subject, reliable prognostic indicators to
predict whether a particular tumour is likely to recur or
metastasise have not been established, although thickness
and location of the tumour, its mitotic rate or histopatho-
logical features of the associated acquired melanosis, if any,
have been suggested as such (Jay, 1965; Silvers et al., 1979;
Crawford, 1980; Liesegang & Campbell, 1980; McGhee et
al., 1982; Benderitter et al., 1985; Folberg et al., 1985b;
Guillen et al., 1985; Jeffrey et al., 1986; Stefani, 1986a,b).
S-100 protein, an acidic cytoplasmic and nuclear antigen
of unknown function present in diverse normal and neoplas-
tic human cell types (Kahn et al., 1983; Vanstapel et al.,
1985, 1986; Haimoto et al., 1987), and neuron-specific
enolase (NSE), a rather widely distributed glycolytic iso-
enzyme primarily found in neuronal and neuroectodermal
cells (Vinores et al., 1984; Haimoto et al., 1985), have been
established as markers for melanoma of the skin (Cochran et
al., 1982; Nakajima et al., 1982; Springall et al., 1983;
Kindblom et al., 1984; Hachisuka et al., 1986) and of the
choroid (Nakajima et al., 1982; Cochran et al., 1983; Royds
et al., 1983; Margo & Lavellee, 1986; Garrido & Arra, 1987;
Fuchs et al., 1988). Both of these markers have also been put
forward as possible prognostic indicators in cutaneous and
choroidal melanoma (Royds et al., 1982, 1983; Dhillon &
Rode, 1982; Rode & Dhillon, 1984; Williams et al., 1986;
Hirano, 1986; Kernohan & Rankin, 1987).
The purpose of the present study was to evaluate whether
any of the previously suggested histopathological features of
conjunctival melanomas or their immunohistochemical reac-
tivity for S-100 protein and NSE could be related to the
prognosis in 26 patients with complete follow-up
information.
Materials and methods
Clinical review
During the years 1967-1987 specimens from 26 white Cauca-
sian patients with a primary malignant melanoma of the
conjunctiva have been examined in the Ophthalmic Path-
ology Laboratory, Department of Ophthalmology, Helsinki
University Central Hospital. The clinical histories, the treat-
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ment given and complete follow-up information (Figure 1)
were retrieved from the records of all the hospitals where the
patients had been treated for conjunctival melanoma and its
metastases, from the Finnish Population and Cancer
Registries and by contacting the patient when other sources
of information were inconclusive. All death certificates and
autopsy protocols were also reviewed. The location of con-
junctival tumours (Table I) was recorded as limbal, caruncu-
lar, bulbar (without limbal or caruncular involvement),
palpebral (limited to tarsal conjunctiva) or diffuse (involving
two or more of these areas, or more than one quadrant of
the bulbar conjunctiva). The size of the tumour (Table I) was
either retrieved from the case records or estimated from
clinical photographs by assuming that the average cornea is
11 mm in diameter.
Histological specimens
In addition to the specimens on file in the Ophthalmic
Pathology Laboratory, all available histopathological mater-
ial from other hospitals where the patients had been treated
was acquired for study. Both the original histological
sections and the paraffin blocks for immunohistochemical
studies could be retrieved from all but two of the 26 primary
tumours, from nine of the eleven recurrent lesions, and from
four of the five metastases that had been surgically removed
or biopsied (Table I). Only slides were available from a fine
needle aspiration biopsy of one lymph node metastasis
(case 8/2). The depth of invasion was measured from the
thickest part of the conjunctival tumours with a calibrated
ocular micrometer. In seven cases a reliable measurement
was not possible because the sections were either oblique or
were not from the thickest part of the tumour as compared
with the clinical photographs. In addition, the average
number of mitoses per five high power ( x400) microscopic
fields was recorded as few (less than five mitoses), moderate
(six to ten mitoses) or many (more than ten mitoses). The
presence of proliferating intraepithelial melanocytes adjacent
to the invasive tumour (primary acquired melanosis or radial
growth phase) was recorded and classified according to
Folberg et al. (1985a).
Immunohistochemical staining
All specimens were formalin-fixed and paraffin-embedded.
After deparaffinisation in xylene and rehydration in an
ethanol series, endogenous peroxidase activity was destroyed
by a 30-min treatment in methanol containing 0.5% hydro-
gen peroxide. The sections were then incubated for 30min
with normal serum (Vectastain ABC kits for Rabbit and
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Figure 1 Clinical course of the 26 primary conjunctival melanomas studied. R = recurrent and M = metastatic tumour. Ec =local
excision, en =enucleation, ex =exenteration, nd = radical neck dissection, ph =photocoagulation, cr = cryocoagulation, rd = radio-
therapy and ch =chemotherapy. 1 =dead of metastatic melanoma, 2=dead of intercurrent disease.
Mouse IgG; Vector Laboratories, Burlingame, CA, USA;
dilution 1:50) in a moist chamber at room temperature, and
for 60min with the primary antibodies at 37°C. The primary
rabbit antisera (anti-neuron specific enolase A589, lot 084;
dilution 1:600 and anti-cow S1OO Z311, lot 113; dilution
1:100) were purchased from Dakopatts a/s (Glostrup,
Denmark). The monoclonal anti-macrophage antibody
RPN.701 (lot 1; undiluted) recognising two determinants on
human macrophages was obtained from Amersham
Laboratories (Amersham, UK). It cross-reacts with some
granulocytes and many squamous epithelia (Isaacson &
Jones, 1983). DAKO-LC (lot 123; dilution 1:10), a mixture
of two monoclonal antibodies recognising different epitopes
on human leukocyte common antigen (Warnke et al., 1983),
a group of membrane glycoproteins on most types of human
leukocytes, was also purchased from Dakopatts a/s.
Subsequently the sections were treated with biotinylated
anti-rabbit and anti-mouse secondary antisera (Vectastain
ABC kits; 1:200) and then with the avidin-biotinylated
peroxidase complex (Vectastain ABC kit reagents A and B,
both diluted 1:160) in a moist chamber at 37°C for 30min.
All immunoreagents were diluted with phosphate-buffered
saline (PBS; pH 7.4) containing 2% (w/v) bovine serum
albumin (E. Merck, Darmstadt, FRG). Between every step,
the sections were washed for three 10-min changes in PBS.
The peroxidase reaction was developed with 3-amino-9-
ethylcarbazole (Sigma; St Louis, MO; 40mg dissolved in
12ml of N,N-dimethylformamide and 200ml of 0.05 M
sodium acetate buffer, pH5.0, containing 0.03% hydrogen
peroxide) which gives a red reaction product contrasting
with brown melanin pigments. To enable evaluation of the
positive staining reaction in more heavily pigmented lesions
the peroxidase reaction was also developed with 3,3'-
diaminobenzidine tetrahydrochloride (Sigma; 150mg in 16ml
of dimethylsulphoxide and 200ml of PBS containing 0.03%
hydrogen peroxide) which gives a dark brown reaction
product resistant to hydrogen peroxide, melanin being then
bleached for 18 h in a solution containing 3% (v/v) hydrogen
peroxide and 1% (w/v) disodium hydrogen phosphate
(Romeis, 1968).
The percentage of melanoma cells reacting positively for
S-100 protein and neuron-specific enolase was recorded. The
extent of lymphocytic infiltration (LC-positive cells) at the
base of the tumour was graded as mild, moderate or strong
according to Jeffrey et al. (1986). In addition, the number of
infiltrating LC-positive lymphocytes and RPN.701-positive
macrophages within the melanomas was graded as few (0-4
cells), moderate (5-14 cells) or many (more than 15 cells per
x 400 microscopic field).
For comparative purposes, three cases of primary acquired
melanosis of the conjunctiva with and three cases without
melanocytic atypia (Folberg et al., 1985a), as well as three
conjunctival naevi, were selected from the files of the
Ophthalmic Pathology Laboratory. In all specimens con-
junctival nerve processes and Schwann cells served as inter-
nal positive controls for NSE and S-100 protein, respectively.
Omission of the primary or secondary antibody and substi-
tution of the primary antibody with normal rabbit serum or
an unrelated murine monoclonal antibody (Anti-Cytokeratin
PKK1; Labsystems, Helsinki, Finland) were used as negative
controls.
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Results
Clinical course
The mean follow-up time in the present series was 5.5 years,
ranging from 8 months to 17 years (Figure 1). The primary
therapy most often used was local resection, sometimes
combined with cryocoagulation or radiotherapy. Enuclea-
tion, exenteration and radical neck dissection were seldom
used (Figure 1). Eight of the 26 primary conjunctival melan-
omas studied have later recurred and eight have metastasised
(Table II). Seven of the eight metastatic cases have resulted
in the death of the patient (Figure 1). Among the 16 primary
limbal melanomas, recurrence was observed three times and
metastasis twice. The latter were large tumours which
extended to the deep margin of the histopathological speci-
men (Table I). Furthermore, nine patients with limbal mela-
nomas have survived 5 years or longer without either
recurrence or metastasis. In contrast, six of the ten patients
with a bulbar, caruncular, palpebral or diffuse primary
melanoma have died of metastatic disease 2-6 years after the
initial operation (mean interval 3.8 years; Figure 1). Of the
remaining four patients, three are alive but have not yet been
followed for 5 years and one patient with a large caruncular
tumour died of intercurrent disease soon after the operation.
Light microscopy
In four cases, all of which were limbal and have neither
recurred nor metastasised, the thickness of the primary
tumour was 0.8mm or less (Table I). Two of the six primary
tumours that later metastasised, and whose depth could
reliably be determined, were less than 1.5mm thick. Only
four of the 12 primary melanomas 1.5mm or more in depth
have metastasised. The primary tumour was the thickest
lesion diagnosed before metastases became apparent in every
case.
Nineteen primary tumouts were of the epitheloid cell type,
six of the mixed cell type and one of the spindle cell type
(TableI). One of the epithelioid cell melanomas was very
pleomorphic and contained many giant tumour cells. Five
epithelioid and three mixed cell melanomas metastasised.
Adjacent intraepithelial involvement by atypical melanocytes
(primary acquired melanosis or radial growth phase) was
observed in 12 of the 19 cases of primary melanoma where
sufficient surrounding epithelium was available for study
(Table I). Three melanomas with and two without intraepi-
thelial involvement later metastasised. The mitotic rate was
low in most of the primary tumours and it was generally not
noticeably higher in cases that later recurred or metastasised,
although in several secondary tumours the number of
mitoses was greater than in the corresponding primaries
(Table I). Frank invasion of blood or lymphatic vessels was
observed in one case only (case 19).
Immunohistochemistry
Tumour cells reacting with the antiserum to S-100 protein
(Figure 2b) were found in all conjuctival melanomas studied
(Table I)..The intensity of the reaction and the number of
positive cells varied between individual tumours, and pig-
mented cells were generally only faintly labelled. The deeper
Table II Clinical characteristics of the 26 primary conjunctival
melanomas according to their location
Mean age
Location Number (years) Recurrences Metastases
Limbal 16 (62%) 60 3 (19%) 2 (12%)
Bulbar 4 (15%) 53 1 (25%) 2 (50%)
Caruncular 2 (8%) 55 1 (50%)
Palpebral 3 (12%) 72 3 (100%) 3 (100%)
Diffuse 1 (4%) 47 - 1 (100%)
Total 26 59 8 (31%) 8 (31%)
parts of the tumour could be labelled more intensely than
their superficial parts, but in most cases there was no
obvious difference in this respect. These deeper parts gener-
ally consisted of smaller cells without marked nuclear pleo-
morphism and lacked prominent nucleoli. Nests of naevoid
cells were noted in several specimens adjacent to the melan-
oma, and these were often more strongly labelled than the
mclanoma cells. The overall number of positive melanoma
cells tended to be smaller in metastatic lesions than in
corresponding primary tumours (TableI). The atypical
melanocytes in primary acquired melanosis reacted in every
case strongly for S-100 protein, rendering evaluation of its
extent easy (Figure 2g and h). Many normal melanocytes of
the conjunctiva were also moderately labelled (Figure 2f),
especially in the palpebral conjunctiva. The three conjunc-
tival naevi were uniformly positive for S-100 protein.
Ten of the 26 primary melanomas studied reacted posi-
tively for neuron-specific enolase (Figure 2c). More than
20% of the neoplastic cell population was positively labelled
in five cases only, one of which has metastasised (Table I). In
two of the four metastatic lesions available for study at least
half of the tumour cells were labelled, while the other two
remained essentially negative. Normal melanocytes of the
conjunctiva, as well as atypical melanocytes in primary
acquired melanosis and conjunctival naevi were negative for
NSE without exception.
The amount of the inflammatory infiltrate was generally
greater around the tumour than it was within it (Table I).
Larger numbers of LC-positive lymphocytes and macro-
phages reacting with the anti-macrophage antibody were
observed within the primary tumour in eight and seven
cases, respectively (Figure 2d and e). The infiltrating
lymphocytes were often situated in the immediate vicinity of
blood vessels, while macrophages were more randomly distrib-
uted. The antimacrophage antibody additionally reacted with
the conjunctival epithelial cells in a way similar to the anti-
keratin antibody. The amounts of lymphocytes and macro-
phages showed no obvious correlation to treatment outcome
(Table I).
Discussion
In line with cutaneous melanomas, it has been documented
that the depth of invasion, either alone (Silvers et al., 1979;
Liesegang & Campbell, 1980; Jeffrey et al., 1986; Folberg et
al., 1985b; McGhee et al., 1982) or in combination with the
rate of mitosis (Stefani, 1986a,b), is an important prognostic
factor of conjunctival melanomas. However, care should be
taken to section all specimens perpendicularly to the surface
of the conjunctiva at several levels to ensure reliable results
(Silvers et al., 1979; Folberg et al., 1985b). Since this is not
always possible in retrospective studies, the critical thickness
indicative of high metastatic risk remains controversial.
Although initially reported to be 1.5mm (Silvers et al., 1979;
McGhee et al., 1982; Jeffrey et al., 1986), a limit of 0.8mm
has more recently been put forward (Folberg et al., 1985b).
There were two primary tumours leading to metastatic
disease that were less than 1.5mm in thickness in the present
material, and even more superficially invasive conjunctival
melanomas are known to metastasise, supporting the latter
limit (Crawford, 1980; Folberg et al., 1985b). The value of
the depth of invasion as a prognostic indicator is, however,
diminished by the fact that many tumours more than 1.5mm
in depth do not metastasise, as was also observed in the
present study.
Other clinicopathological features indicative of poor prog-
nosis have been suggested. These include origin from pre-
viously existing naevus (Liesegang & Campbell, 1980), young
age of the patient (Crawford, 1980), involvement of the
caruncular or palpebral conjunctiva (Jay, 1965; Jeffrey et al.,
1986; Crawford, 1980; Silvers et al., 1979; Stefani, 1986a,b),
high rate of mitosis (Crawford, 1980; Folberg et al., 1985b;CONJUNCTIVAL MELANOMAS 265
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Figure 2 (a) Epithelioid cell type primary malignant melanoma of the conjunctiva with marked inflammatory infiltration among
tumour nests (Case 15; HE, x350). (b) The neoplastic cells are strongly positive for S-100 protein. Inflammatory cells remain
negative ( x 350). (c) Some of the melanoma cells show weak to moderate positive reaction for neuron-specific enolase ( x 350). (d)
Most inflammatory cells are positive for leukocyte common antigen, while melanoma cells remain negative ( x 350). (e) Many of
the inflammatory cells react with the anti-macrophage antibody (x 350). (f) Weak reaction for S-100 protein in normal
melanocytes of the conjunctiva (arrowheads). The dendritic suprabasal cell (arrow) is probably a Langerhans cell (x270). (g)
Infiltration of conjunctival epithelium by abnormal melanocytes in primary acquired melanosis (HE, x 270). (h) These melanocytes
react strongly for S-100 protein (x 270).
Benderitter et al., 1985; Stefani, 1986a,b), weak inflam-
matory reaction (Crawford, 1980; Folberg et al., 1985b),
invasion of blood vessels (McGhee et al., 1982; Benderitter
et al., 1985), and atypia observed in the associated primary
acquired melanosis (PAM) (Folberg et al., 1985b). In the
present series, the amount of lymphocytes or macrophages
demonstrable immunohistochemically, the cell type or the
presence of primary acquired melanosis were not obviously
correlated to prognosis. The mitotic rate, although often
greater in metastatic and recurrent lesions, was not particu-
larly high in most of the corresponding primary tumours. As
in previous series, involvement of palpebral conjunctiva was
associated with poor prognosis, which may in part be
dependent on the greater size of the primary tumours
(Silvers et al., 1979; Crawford, 1980; Jeffrey et al., 1986).
Neither of the two caruncular cases in the present series
allow any firm conclusions as to treatment outcome, but
caruncular melanomas are thought to have a rather poor
prognosis (Silvers et al., 1979; Crawford, 1980). It is, indeed,
quite clear that limbal melanomas have a much better
prognosis than their counterparts in other areas of the
conjunctiva.
S-100 protein was detected in all conjunctival melanomas
and naevi studied, confirming previous observations266 U. FUCHS et al.
(Kindblom et al., 1984; Holbach & Hofmann, 1987). As has
been reported for cutaneous and choroidal melanomas, the
reaction intensity in individual cells was quite variable and
deeply pigmented cells were generally only weakly reactive
(Nakajima et al., 1982; Royds et al., 1982; Springall et al.,
1983; Hachisuka et al., 1986; Fuchs et al., 1988). Whether
immunoreactivity for S-100 protein is a prognostic indicator
in cutaneous melanomas is disputed. While some authors
have failed to observe any correlation to prognosis
(Hachisuka et al., 1986), others have claimed that strong
reaction for S-100 protein in primary melanomas could
denote either improved survival (Kernohan & Rankin, 1987)
or early metastasis (Rode & Dhillon, 1984; Williams et at.,
1986). In the present series, there was no difference in the
reactivity between the primary lesions that had later meta-
stasised and those that had not. However, the number of
positively staining tumour cells was smaller and the overall
reaction intensity generally less intense in metastatic than in
primary lesions. Such a difference has not been reported for
cutaneous melanomas (Nakajima et al., 1982; Springall et
al., 1983; Hachisuka et al., 1986).
The antiserum to neuron-specific enolase (NSE) reacted
only with a minority of the melanoma cells and did not label
any of the naevi studied. These results are in line with
several previous reports on cutaneous melanoma, in which a
weak and patchy reaction for NSE has been obtained in less
than one half of the studied tumours (Springall et al., 1983;
Hachisuka et al., 1986; Thomas et al., 1987). In other
studies, however, almost all cutaneous melanomas have been
positively labelled (Dhillon & Rode, 1982; Rode & Dhillon,
1984; Royds et al., 1982; Hirano, 1986), possibly indicating
differences in antibody specificity.
Rode & Dhillon (1984) have suggested that NSE is
preferentially expressed in metabolically active malignant
melanocytes and have shown that primary tumours strongly
positive for NSE give rise to metastases more rapidly than
those reacting only weakly. Some metastases and recurrences
of the conjunctival melanomas presently studied did in fact
have greater numbers of NSE-positive tumour cells than the
corresponding primary lesions, which would be compatible
with this theory. However, at least five of the eight primary
conjunctival melanomas that later metastasised contained
insignificant numbers of NSE-positive tumour cells, and
three of the five cases in which more than one-fifth of the
tumour cells were positive for NSE neither recurred nor
metastasised, indicating that immunoreactivity for NSE can-
not predict which lesions are prone to metastasis. Indeed,
even in the study by Rode & Dhillon (1984), weakly NSE-
positive primary cutaneous melanomas metastasised more
often than strongly positive tumours, and several metastases
showed a weaker reaction than the corresponding primary
tumours. Furthermore, none of the six NSE-positive skin
melanomas of Springall et al. (1983) metastasised, and none
of their 25 metastatic melanomas were positive for NSE.
Although our results do not support the theory, suggested
for skin melanomas, that immunoreactivity for S-100 protein
and NSE could be used as prognostic indicators in conjunc-
tival melanoma, S-100 protein was found to be a useful
adjunct not only in the diagnosis of this disease, but also in
easily delineating the extent of the associated intraepithelial
involvement. Since a number of recent histopathological
studies on conjunctival melanomas have shown that conven-
tional histopathological criteria do not provide consistent
criteria for predicting their prognosis, attention should be
turned towards new metabolic and antigenic properties of
these tumours, as well as to those host factors that ultima-
tely determine whether micrometastases will lead to frank
metastatic disease.
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